A move to help patients or create exclusive cartel? Mixed views on PhRMA's big change

11 May 2017

Ambitious French drugmaker Ipsen (Euronext: IPN) and reproductive health specialist Ferring Pharmaceuticals are among the 22 companies which have ceased to be members or associates of Pharmaceutical and Research Manufacturers of America (PhRMA) after the group changed its membership criteria.

PhRMA, the world’s best-known trade group and lobbyist representing pharma companies in the USA, has billed its change as a move towards making sure its members are investing sufficiently in research and development (R&D), but a consumer rights advocacy group has reacted with cynicism.

"Pharma is among the most distrusted and disfavored industries, and Americans want to turn its business model upside down"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK